Non-disclosure preimplantation genetic diagnosis for Huntington's disease: practical and ethical dilemmas

1998 ◽  
Vol 18 (13) ◽  
pp. 1422-1426 ◽  
Author(s):  
Peter R. Braude ◽  
Guido M. W. R. de Wert ◽  
Gerry Evers-Kiebooms ◽  
Rachel A. Pettigrew ◽  
Joep P. M. Geraedts
2002 ◽  
Vol 10 (10) ◽  
pp. 591-598 ◽  
Author(s):  
Karen Sermon ◽  
Martine De Rijcke ◽  
Willy Lissens ◽  
Anick De Vos ◽  
Peter Platteau ◽  
...  

2011 ◽  
Vol 20 (4) ◽  
pp. 368-375 ◽  
Author(s):  
Maartje C Van Rij ◽  
◽  
Marjan De Rademaeker ◽  
Céline Moutou ◽  
Jos CFM Dreesen ◽  
...  

2021 ◽  
Vol 5 (1) ◽  
Author(s):  
Joep P.M. Geraedts ◽  

Huntington’s disease (HD) is an autosomal dominant disease that immensely impacts the affected families. However, the transmission of the disease from carriers to their offspring could be prevented. Prenatal diagnosis (PND) and preimplantation genetic diagnosis (PGD) are the only two available reproductive options for the carriers at risk to have disease-free children. PND for HD could be done through two kinds of genetic testing: direct and indirect. The same approaches are available for preimplantation genetic testing. In addition, a third alternative is nondisclosure testing, which is only available in the case of PGD. The pros and cons of different approaches are discussed. However, only a relatively few at-risk parents opt for PND and PGD. Furthermore, compared to PND, PGD is even more seldom opted for as a reproductive option.


2012 ◽  
Vol 20 (9) ◽  
pp. 1010-1010 ◽  
Author(s):  
Maartje C Van Rij ◽  
◽  
Marjan De Rademaeker ◽  
Céline Moutou ◽  
Jos C F M Dreesen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document